Immunogenicity of candidate chimeric DNA vaccine against tuberculosis and leishmaniasis

Vaccine

Volumn 27, Issue 37, 2009, Pages 5152-5160

  Dey, Ayan ^a   Kumar, Umesh ^a   Sharma, Pawan ^b   Singh, Sarman ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Chimera; esat 6; IFN ; Kinesin motor domain; Multivalent Vaccine; Visceral leishmaniasis

Indexed keywords

BCG VACCINE; CHIMERIC PROTEIN; DNA VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; INTERLEUKIN 2; KINESIN; LEISHMANIA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LEISHMANIA DONOVANI; LEISHMANIASIS; MIXED INFECTION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; INTERFERON-GAMMA; INTERLEUKIN-2; KINESIN; LEISHMANIA DONOVANI; LEISHMANIASIS; LEISHMANIASIS VACCINES; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PROTOZOAN PROTEINS; SPLEEN; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA;

EID: 67650762221     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.100     Document Type: Article

References (43)

1. Herwaldt B.L. Leishmaniasis. Lancet 354 (1999) 1191-1199
2. Raja A. Immunology of tuberculosis. Indian J Med Res 120 (2004) 213-232
3. + T cells in lungs following aerosol infection with Mycobacterium tuberculosis. Infect Immun 67 (1999) 3242-3247
4. Peruhype-Magalhães V., Martins-Filho O.A., Prata A., Silva Lde A., Rabello A., Teixeira-Carvalho A., et al. Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. Scand J Immunol 62 5 (2005) 487-495
5. Kemp M., Kurtzhals J.A., Bendtzen K., Poulsen L.K., Hansen M.B., Koech D.K., et al. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun 61 (1993) 1069-1073
6. Montalban C., and Callejia J.L. Leishmaniasis masking tuberculosis. Lancet 335 8684 (1990) 299-300
7. Ting L.M., Kim A.C., Cattamanchi A., and Ernst J.D. Mycobacterium tuberculosis inhibits IFN-γ transcriptional responses without inhibiting activation of STAT1. J. Immunol. 163 (1999) 3898
8. Chaudhuri A. Leishmaniasis masking tuberculosis. Lancet 2 8676 (1989) 1396-1397
9. Amprey J.L., Spath G.F., and Porcelli S.A. Inhibition of CD1 expression in human dendritic cells during intracellular infection with Leishmania donovani. Infect Immun 72 1 (2004) 589-592
10. Meier C.L., Svensson M., and Kaye P.M. Leishmania-Induced inhibition of macrophage antigen presentation analyzed at the single-cell level. J Immunol 171 (2003) 6706-6713
11. Chadha V.K., Kumar P., Gupta J., Jagannatha P.S., Lakshminarayana, Magesh V., et al. The annual risk of tuberculous infection in the eastern zone of India. Int J Tuberc Lung Dis 8 5 (2004) 537-544
12. el-Safi1 S.H., Hamid N., Omer A., Abdel-Haleem A., Hammad A., Kareem H.G., et al. Infection rates with Leishmania donovani and Mycobacterium tuberculosis in a village in eastern Sudan. Trop Med Int Health 9 12 (2004) 1305-1311
13. Pandey K., Sinha P.K., Ravidas V.N., Kumar N., Verma N., Lal C.S., et al. Nexus of infection with human immunodeficiency virus, pulmonary tuberculosis and visceral leishmaniasis: a case report from Bihar, India. Am J Trop Med Hyg 72 1 (2005) 30-32
14. Wang J., Vanley C., Miyamoto E., Turner J.A., and Peng S.K. Coinfection of visceral leishmaniasis and Mycobacterium in a patient with acquired immunodeficiency syndrome. Arch Pathol Lab Med 123 9 (1999) 835-837
15. Brandt L., Oettinger T., Holm A., Anderson A.B., and Anderson P. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol 157 (1996) 3527-3533
16. van Pinxteren L.A., Ravn P., Agger E.M., Pollock J., and Anderson P. Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin Diagn Lab Immunol 7 (2000) 155-160
17. Pittus N.C.G.V., Gamieldien J., Hide W., Brown G.D., Siezen R.J., and Beyers A.D. The esat-6 gene cluster of Mycobacterium tuberculosis and other high G + C Gram-positive bacteria. Genome Biol 2 10 (2001) 1-18
18. Pym AS. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003;9 [advance online publication].
19. Brandt L., Elhay M., Rosenkrands I., Lindblad E.B., and Andersen P. esat-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 68 (2000) 791-795
20. Kamath A.T., Feng C.G., Macdonald M., Briscoe H., and Warwick J.B. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infec Immun 67 (1999) 1702-1707
21. Dey A., Sharma P., Redhu N.S., and Singh S. Kinesin Motor Domain of Leishmania Donovani as future vaccine candidate. Clin Vacc Immunol 15 5 (2008) 836-842
22. Sivakumar R., Sharma P., Chang K.P., and Singh S. Cloning, expression and purification of a novel recombinant antigen Leishmania donovani. Protein Expr Purif 46 (2006) 156-165
23. Burns Jr. J.M., Shreffler W.G., Benson D.R., Ghalib H.W., Badaro R., and Reed S.G. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral Leishmaniasis. Proc Natl Acad Sci USA 90 (1993) 775-779
24. Sivakumar R., Dey A., Sharma P., and Singh S. Expression and Characterization of a recombinant kinesin antigen from an old Indian strain (DD8) of Leishmania donovani and comparing it with a commercially available antigen from a newly isolated (KE-16) strain of L. donovani. Infect Genet Evol 8 (2008) 313-322
25. Singh S., Gilman-Sachs A., Chang K.P., and Reed S.G. Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. J Parasitol 81 (1995) 1000-1003
26. Iwai S., Ishiji A., Mabuchi I., and Sutoh K.A. Novel actin-bundling kinesin-related protein from Dictyostelium discoideum. J Biol Chem 6 (2004) 4696-4704
27. Takagi H., Islam M.Z., Itoh M., Islam A.U., Saifuddin Ekram A.R., Hussain S.M., et al. Short report: production of recombinant kinesin-related protein of Leishmania donovani and its application in the serodiagnosis of visceral leishmaniasis. Am J Trop Med Hyg 76 5 (2007) 902-905
28. Singh H., and Raghava G.P.S. ProPred: prediction of HLA-DR binding sites. Bioinformatics 17 12 (2001) 1236-1237
29. Donnelly M.L., Hughes L.E., Luke G., Mendoza H., ten Dam E., Gani D., et al. The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J Gen Virol 82 5 (2001) 1027-1041
30. Zhu M., Xu X., Liu H., Liu X., Wang S., Dong F., et al. Enhancement of DNA vaccine potency against herpes simplex virus 1 by co-administration of an interleukin-18 expression plasmid as a genetic adjuvant. J Med Microbiol 52 3 (2003) 223-228
31. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
32. Seder R.A., and Gurunathan S. DNA vaccines-designer vaccines for the 21st century. N Engl J Med 341 4 (1999) 277-278
33. Abdelnoor A.M. Plasmid DNA vaccines. Curr Drug Targets Immune Endocr Metabol Disord 1 1 (2001) 79-92
34. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 5388 (1998) 476-480
35. Sukumaran B., Tewary P., Saxena S., and Madhubala R. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 21 (2003) 1292-1299
36. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., and Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174 (2005) 7160-7171
37. Khera A., Singh R., Shakila H., Rao V., Dhar N., Narayanan P.R., et al. Elicitation of efficient, protective immune responses by using DNA vaccines against tuberculosis. Vaccine 23 (2005) 5655-5665
38. Hasan U.A., Abai A.M., Harper D.R., Wren B.W., and Morrow W.J. Nucleic acid immunization: concepts and techniques associated with third generation vaccines. J Immunol Methods 229 (1999) 1-22
39. McDonell W.M., and Askari F.K. DNA vaccines. N Engl J Med 334 1 (1996) 42-45
40. de Felipe P. Skipping the co-expression problem: the new 2A "CHYSEL" technology. Genet Vaccines Ther 2 13 (2004) 10.1186/1479-0556-2-13
41. Lyadova I.V., Vordermeier H.M., Eruslanov E.B., Khaidukov S.V., Apt A.S., and Hewinson R.G. Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-γ in their lungs. Clin Exp Immunol 126 (2001) 274-279
42. Aguilar-Be I., da Silva Zardo R., Paraguai de Souza E., Borja-Cabrera G.P., Rosado-Vallado M., Mut-Martin M., et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 73 2 (2005) 812-819
43. Sharma P., Kumar A., Batni S., and Chauhan V.S. Co-dominant and reciprocal T-helper cell activity of epitopic sequences and formation of junctional B-cell determinants in synthetic T:B chimeric immunogens. Vaccine 11 13 (1993) 1321-1326